Biopharmaceutical company Incyte (Nasdaq:INCY) disclosed on Thursday that the US Food and Drug Administration (FDA) has accepted for priority review its Biologics License Application (BLA) for retifanlimab.
An intravenous PD-1 inhibitor, retifanlimab is being reviewed as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy.
SCAC is associated with human papillomavirus (HPV) and HIV infections and accounts for almost 3% of digestive system cancers.
Patients with metastatic SCAC have a poor five-year survival, and there are no FDA-approved treatments for patients who have progressed after first-line chemotherapy.
The Prescription Drug User Fee Act (PDUFA) target action date is 25 July 2021.
Incyte's BLA submission is based on data from the company's Phase 2 POD1UM-202 trial evaluating retifanlimab in previously treated patients with locally advanced or metastatic SCAC who have progressed on, or are intolerant of, standard platinum-based chemotherapy. The trial enrolled 94 patients and resulted in an objective response rate (ORR) of 14% for retifanlimab monotherapy. Retifanlimab 500 mg is administered intravenously every four weeks.
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring
Henry Schein introduces equipment repair subscription - Henry Schein Thrive Service Plus
Seres Therapeutics provides business updates and reports Q2 2023 financial results